-
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib
At this year’s recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Zhang Guiming from Qingdao University Affiliated…
-
Understanding and Managing Chronic Hepatitis B: The Importance of Detailed Assessment
Since the introduction of the first oral nucleos(t)ide analogs (NAs) lamivudine for the treatment of chronic hepatitis B (CHB) in China in 1998, there has been a continuous effort over 25 years to explore various generations of drugs by medical, pharmaceutical, and technological researchers. The NA family has expanded to include entecavir, telbivudine, tenofovir disoproxil…
-
CASH interview | Professor Jinghui Zhang: Monitoring clonal hematopoiesis in pediatric patients to help improve long-term prognosis
Clonal hematopoiesis usually refers to myeloid cell proliferation caused by genetic mutations in hematopoietic stem cells, and is also the basis of the pathogenesis of various blood diseases; monitoring clonal hematopoiesis can enable early detection of hematological malignancies. At the 4th CASH held recently, Professor Jinghui Zhang from St. Jude Children’s Research Hospital shared the…
-
Efficacy and Safety of Crovalimab in Complement Inhibitor-Naive Patients with PNH
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating hematological disease caused by a genetic mutation in the PIG-A gene, resulting in deficient glycosylphosphatidylinositol (GPI) anchor synthesis. This deficiency affects…
-
Immunogenic Cell Death in Hematological Malignancy Therapy
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, are characterized by abnormalities in the quantity and quality of blood cells. Immunogenic cell death (ICD) is a unique mechanism that triggers…
-
Gene Therapy Using BCMA/CD3 Bispecific Antibody-Encoding Plasmid DNA: A Novel Approach for Treating Multiple Myeloma
Multiple myeloma (MM) remains a significant challenge in the field of hematology, characterized by its incurability and frequent relapses despite advancements in treatment. In the quest for more effective therapies,…
-
BSA-AIE Nanoparticles for Immunogenic Cell Death Immunotherapy of Multiple Myeloma
Multiple myeloma (MM) is a hematological cancer characterized by the proliferation of malignant plasma cells in the bone marrow. Despite advancements in MM treatment, relapses and the spread of cancerous…
-
Unveiling the Role of BMSCs in NK Cell Exhaustion via the Tim-3/Galectin-9 Pathway in Multiple Myeloma
MM is a hematological neoplasia characterized by the clonal proliferation of aberrant plasma cells, leading to significant health complications. Understanding the mechanisms by which BMSCs contribute to NK cell exhaustion,…
Connecting Medical Expertise through Media